Loading
Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.
Aurélien Marabelle is Clinical Director of the Cancer Immunotherapy Program (DITEP) at Gustave Roussy. His specialisms are immuno-oncology, early-phase immunotherapy, MSI-high tumours and intratumoural therapy, with a focus on PD-1 and immune checkpoint inhibitors. He was lead author of the KEYNOTE-158 analysis in the Journal of Clinical Oncology, which reported the efficacy of pembrolizumab in non-colorectal cancers with high microsatellite instability or mismatch repair deficiency and supported the drug's tumour-agnostic approvals. He now leads early-phase immunotherapy trials at DITEP and works on delivering immunotherapy directly into tumours. His publications are listed on PubMed.
Shares Gustave Roussy, PD-1, Pembrolizumab, Immune checkpoint inhibitors.
Shares KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer, Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1.
Shares KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer, PD-1, Pembrolizumab.
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Pembrolizumab, Immune checkpoint inhibitors.
Shares KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer, Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1.
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1, Immune checkpoint inhibitors.
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1, Pembrolizumab, Immune checkpoint inhibitors.